[1] Kuźnik A., Październiok-Holewa A., Jewula P., Kuźnik N., Bisphosphonates—Much More than Only Drugs for Bone Disease, European Journal of Pharmacology, 866: 172773 (2020).
[2] Yang M., Yu X., Management of Bone Metastasis with Intravenous Bisphosphonates in Breast Cancer: A Systematic Review and Meta-Analysis of Dosing Frequency, Supportive Care in Cancer, 28: 2533-2540 (2020).
[3] Abdussalam-Mohammed W., Review of Therapeutic Applications of Nanotechnology in Medicine Field and its Side Effects, Journal of Chemical Reviews, 1: 243-251 (2019).
[4] Hosseinzadeh Z., Ramazani A., Razzaghi-Asl N, Plants of the Genus Heracleum as a Source of Coumarin and Furanocoumarin, Journal of Chemical Reviews, 1: 78-98 (2019).
[5] Peddagundam B., Abdul Ahad H., Chinthaginjala H., Ksheerasagare T., Ganthala A K., Gummadisani G.R., The Design of Soft Drugs: Basic Principles, Energetic Metabolite Methods, Approved Compounds, and Pharmaceutical Applications, Journal of Chemical Reviews, 4: p. 241-254 (2022).
[6] Menschutkin N., Ueber Die Einwirkung Des Chloracetyls Auf Phosphorige Säure, Justus Liebigs Annalen der Chemie, 133: 317-320 (1865).
[7] Smith R., Russell R., Bishop M., Diphosphonates and Paget's Disease of Bone, The Lancet, 297, p. 945-947 (1971).
[8] Von Baeyer H., Hofmann K., Acetodiphosphorige Saure, Beitr Dtsch Chem Ges, 30: 1973-1978 (1897).
[9] Fleish H., Neuman W.F., Mechanisms of Calcification: Role of Collagen, Polyphosphates, and Phosphatase, American Journal of Physiology-Legacy Content, 200: 1296-1300 (1961).
[10] Fleisch H., Russell R., A Review of the Physiological and Pharmacological Effects of Pyrophosphate and Diphosphonates on Bones and Teeth, Journal of Dental Research, 51: 323-332 (1972).
[11] Russell R., Hodgkinson A., The Urinary Excretion of Inorganic Pyrophosphate by Normal Subjects and Patients with Renal Calculus, Clinical Science, 31: 51-62 (1966).
[12] Farrell K B., Karpeisky A., Thamm D H., Zinnen S., Bisphosphonate Conjugation for Bone Specific Drug Targeting, Bone Reports, 9: 47-60 (2018).
[13] Maghsoudi S., Hosseini S.A., Ravandi S., A Review on Phospholipid and Liposome Carriers: Synthetic Methods and Their Applications in Drug Delivery, Journal of Chemical Reviews, 4: 346-363 (2022).
[14] Kakanejadifard A., Synthesis, Characterization, Crystal Structure and Density Functional Investigation of Dialkyl(Phenyl((4-(Phenyl Diazenyl)Phenyl) Amino)Methyl) Phosphonate, 333174: (2021).
[15] Faghihian H.,Yaghobb Nejadasl H., Synthesis, Characterization and Application of a Novel Zirconium Phosphonate Ion-Exchanger for Removal of Ni2+, Cu2+ and Zn2+ from Aqueous Solutions, 333174. 30: 23-31 (2011).
[16] Russell R.G.G., Bisphosphonates: From Bench to bedside, Annals of the New York Academy of Sciences, 1068: 367-401 (2006).
[17] J. Roelofs A., Thompson K., H. Ebetino F., J. Rogers M., P. Coxon F., Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages, Current Pharmaceutical Design, 16: 2950-2960 (2010).
[18] Edwards B.J., Gounder M., McKoy J.M., Boyd I., Farrugia M., Migliorati C., Marx R., Ruggiero S., Dimopoulos M., Raisch D.W, Pharmacovigilance and Reporting Oversight in US FDA Fast-Track Process: Bisphosphonates and Osteonecrosis of the Jaw, The Lancet Oncology, 9: 1166-1172 (2008).
[19] Heymann D., Ory B., Gouin F., Green J.R., Rédini F., Bisphosphonates: New Therapeutic Agents for the Treatment of Bone Tumors, Trends in Molecular Medicine, 10: 337-343 (2004).
[20] Ponte Fernández N., Estefania Fresco R., Aguirre Urizar J.M., Bisphosphonates and Oral Pathology I. General and Preventive Aspects, Medicina Oral, Patologia Oral Y Cirugia Bucal, 11: E396-400 (2006).
[21] Mbese Z., Aderibigbe B.A., Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer, International Journal of Molecular Sciences, 22: 6869 (2021).
[22] Isla D., Afonso R., Bosch-Barrera J., Martínez N., Zoledronic Acid in Lung Cancer with Bone Metastases: A Review, Expert Review of Anticancer Therapy, 13: 421-426 (2013).
[23] Coleman R., Cook R., Hirsh V., Major P., Lipton A., Zoledronic Acid Use in Cancer Patients: More than Just Supportive Care? Cancer, 117: 11-23 (2011).
[24] Wadsak W., Mitterhauser M., Basics and Principles of Radiopharmaceuticals for PET/CT, European Journal of Radiology, 73: -469 (2010).
[25] Sudbrock F., Fischer T., Zimmermann B., Guliyev M., Dietlein M., Drzezga A., Schomäcker K., Characterization of SnO2-Based 68Ge/68Ga Generators and 68Ga-DOTATATE Preparations: Radionuclide Purity, Radiochemical Yield and Long-Term Constancy, EJNMMI Research, 4: 1-10 (2014).
[26] Velikyan I., Prospective of 68Ga-Radiopharmaceutical Development, Theranostics, 4: 47 (2014).
[27] Ogawa K., Saji H., Advances in Drug Design of Radiometal-Based Imaging Agents for Bone Disorders, International Journal of Molecular Imaging, 2011 (2011).
[28] Bandoli G., Dolmella A., Tisato F., Porchia M., Refosco F., Mononuclear Six-Coordinated Ga (III) Complexes: A Comprehensive Survey, Coordination Chemistry Reviews, 253: 56-77 (2009).
[29] Farhanghi M., Holmes R.A., Volkert W.A., Logan K.W., Singh A., Samarium-153-EDTMP: Pharmacokinetic, Toxicity and Pain response Using an Escalating Dose Schedule in Treatment of Metastatic Bone Cancer, J. Nucl. Med., 33: 1451-1458 (1992).
[30] Pfannkuchen N., Bausbacher N., Pektor S., Miederer M., Rosch F., In Vivo Evaluation of [225Ac] Ac-DOTAZOL for α-Therapy of Bone Metastases, Current Radiopharmaceuticals, 11: 223-230 (2018).
[31] Yadav M.P., Ballal S., Meckel M., Roesch F., Bal C., [177Lu] Lu-DOTA-ZOL Bone Pain Palliation in Patients with Skeletal Metastases from Various Cancers: Efficacy and Safety Results, EJNMMI Research, 10: 1-13 (2020).
[32] Yen N., Azahari K., Wan H.B.W.K., Choong K.K., Radiolabelling and Preliminary Biodistribution Study of Samarium-153-Zoledronic Acid as a Novel Bone Pain Palliative Agent.